Meeting
2023 ASCO Annual Meeting
Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs).
Authors
Sienna Durbin
Massachusetts General Hospital, Boston, MA
Sienna Durbin , Leyre Zubiri , Katherine Perlman , Gabriel Molina , Ted Jacoby , Nishi Shah , Kerry Lynn Reynolds
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2652)
DOI
10.1200/JCO.2023.41.16_suppl.2652
Abstract #
2652
Poster Bd #
494
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo
Poster
2021 ASCO Annual Meeting
Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness.
First Author: Mia Bothwell
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy.
First Author: RuiQui Chen
Poster
2023 ASCO Annual Meeting
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).
First Author: Piyush Grover